Although PD-L1 expression on tumour cells/associated immune cells may predict response to anti-PD1 therapy and is a validated biomarker in certain settings such as upper gastrointestinal cancer and non-small-cell lung cancer, it is often not predictive [22]. Here, CD274 is linked to non-small cell lung carcinoma.